Celltrion, Inc. ((주)셀트리온)
KOSPI Stock Code: 068270 | DART Corp Code: 00413046
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | Celltrion, Inc. |
|---|---|
| Korean legal name | (주)셀트리온 |
| Alternate names | 셀트리온 |
| Market | KOSPI |
| Stock Code | 068270 |
| DART Corp Code | 00413046 |
| CEO | 기우성, 서진석 |
| Business Registration No. | 1338123603 |
| Corporate Registration No. | 1350110034038 |
| Established Date | 1991-02-27 |
| Fiscal Month | 12 |
| KSIC Industry Code | 21100 |
| Address (KO) | 인천광역시 연수구 아카데미로 23 |
| Homepage | https://www.celltrion.com/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415 |
| verified_at | 2026-11-01T02:24:15.615Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: CFS (Consolidated) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 4,162,495,108,881 | KRW 3,557,303,554,371 |
| Operating Income (영업이익) | KRW 1,168,471,345,595 | KRW 492,015,534,847 |
| Net Income (당기순이익) | KRW 1,031,483,789,240 | KRW 418,883,310,404 |
| Total Assets (자산총계) | KRW 22,334,900,189,800 | KRW 21,055,222,437,706 |
| Total Liabilities (부채총계) | KRW 4,982,370,370,686 | KRW 3,475,160,069,015 |
| Total Equity (자본총계) | KRW 17,352,529,819,114 | KRW 17,580,062,368,691 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-10-30 | 20261030000742 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 강경두 |
2026-10-30 | 20261030000741 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 최병욱 |
2026-10-30 | 20261030000740 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 신경하 |
2026-10-30 | 20261030000739 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 양현주 |
2026-10-30 | 20261030000738 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 양성욱 |
2026-10-27 | 20261027000365 | Report on significant holdings of stocks, etc. (General) | 주식등의대량보유상황보고서(일반) | 셀트리온홀딩스 |
2026-10-27 | 20261027800047 | [Corrected description]Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure) | [기재정정]연결재무제표기준영업(잠정)실적(공정공시) | 셀트리온 |
2026-10-26 | 20261026000084 | Decision on Acquisition of Treasury Stock | 주요사항보고서(자기주식취득결정) | 셀트리온 |
2026-10-22 | 20261022800167 | Material Business Matters Related to Investment Decisions (반감기 연장 기술이 적용된 장기 지속형 항APRIL 항체 Licensein 계약 체결) | 투자판단관련주요경영사항 (반감기 연장 기술이 적용된 장기 지속형 항APRIL 항체 Licensein 계약 체결) | 셀트리온 |
2026-10-20 | 20261020000090 | Treasury Stock Acquisition Result Report | 자기주식취득결과보고서 | 셀트리온 |
2026-10-14 | 20261014800646 | Material Business Matters Related to Investment Decisions (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 승인) | 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 승인) | 셀트리온 |
2026-10-12 | 20261012800004 | Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure) | 연결재무제표기준영업(잠정)실적(공정공시) | 셀트리온 |
2026-09-29 | 20260929000153 | Decision on Acquisition of Treasury Stock | 주요사항보고서(자기주식취득결정) | 셀트리온 |
2026-09-23 | 20260923000534 | Report on significant holdings of stocks, etc. (General) | 주식등의대량보유상황보고서(일반) | 셀트리온홀딩스 |
2026-09-23 | 20260923800359 | Material Business Matters Related to Investment Decisions (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 승인) | 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 승인) | 셀트리온 |
2026-09-21 | 20260921800165 | Material Business Matters Related to Investment Decisions (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청 승인(Part1&2)) | 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청 승인(Part1&2)) | 셀트리온 |
2026-09-16 | 20260916800015 | Retirement of Stocks | 주식소각결정 | 셀트리온 |
2026-09-16 | 20260916000002 | Treasury Stock Acquisition Result Report | 자기주식취득결과보고서 | 셀트리온 |
2026-09-07 | 20260907800002 | Material Business Matters Related to Investment Decisions (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인) | 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인) | 셀트리온 |
2026-09-07 | 20260907800004 | Material Business Matters Related to Investment Decisions (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인) | 투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인) | 셀트리온 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415 | verified_at: 2026-11-01T02:24:15.615Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.